Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin-soaked vascular prosthesis for infectious aortic aneurysm or graft infection
jRCTs051180033Recruiting
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rifampicin in Infected Aortic Aneurysm (IAA) and vascular graft infection (VGI). Primary endpoint: Control of infectious symptoms at 12 weeks postoperative. Started Jul 2019; status: recruiting.
02
Drugs
rifampicin
03
Conditions
Infected Aortic Aneurysm (IAA)vascular graft infection (VGI)
Beyond the preview
Go deeper on jRCTs051180033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180033.